The psychometric validation of a 1-week recall period for the OAB-q

International Urogynecology Journal

Volumn 22, Issue 12, 2011, Pages 1555-1563

  Coyne, Karin S ^a   Gelhorn, Heather ^a   Thompson, Christine ^a   Kopp, Zoe S ^b   Guan, Zhonghong ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b PFIZER INC   (United States)

Author keywords

OAB; OAB q; Questionnaire; Recall period; Validation

Indexed keywords

FESOTERODINE;

ADULT; ARTICLE; CONCURRENT VALIDITY; CONTROLLED STUDY; DISCRIMINANT VALIDITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; OVERACTIVE BLADDER QUESTIONNAIRE; PATIENT ASSESSMENT; PATIENT PERCEPTION OF BLADDER CONDITION; PATIENT PERCEPTION OF URGENCY SCALE; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; RELIABILITY; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VALIDATION PROCESS;

EID: 84855230872     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-011-1486-0     Document Type: Article

References (22)

1. Abrams P (2003) Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 62(5 Suppl 2):28-37, discussion 40-42 (Pubitemid 37510015)
2. Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29(1):4-20
3. Leidy NK, Revicki DA, Geneste B (1999) Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 2(2):113-127
4. Coyne KS, Sexton CC, Irwin DE et al (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388-1395 (Pubitemid 351623990)
5. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327-336 (Pubitemid 44175300)
6. Homma Y, Gotoh M (2009) Symptom severity and patient perceptions in overactive bladder: how are they related? BJU Int 104(7):968-972
7. Stull DE, Leidy NK, Parasuraman B, Chassany O (2009) Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 25(4):929-942
8. McColl E (2004) Best practice in symptom assessment: a review. Gut 53(Suppl 4):49-54
9. Wyrwich KW, Tardino VM (2004) A blueprint for symptom scales and responses: measurement and reporting. Gut 53(Suppl 4):45-48
10. FDA: Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. December 2009, U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD, pp 1-39
11. Keller SD, Bayliss MS, Ware JE Jr et al (1997) Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods. Health Serv Res 32(3):367-384 (Pubitemid 27327239)
12. Barr JT, Schumacher GE, Freeman S et al (2000) American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther 22(9):1121-1145
13. Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543-562
14. Vardy MD, Mitcheson HD, Samuels TA et al (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-Reported outcomes: results from VIBRANT-a double-blind, placebo-controlled trial. Int J Clin Pract 63 (12):1702-1714
15. Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11(6):563-574 (Pubitemid 34876130)
16. Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49(6):1079-1086 (Pubitemid 43673993)
17. Kazis LE, Anderson JJ, Meenan RF (1989) Effect sizes for interpreting changes in health status. Med Care 27(3):S178-S189
18. Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res 14(3):849-855 (Pubitemid 40576869)
19. Matza LS, Thompson CL, Krasnow J et al (2005) Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 24(3):215-225 (Pubitemid 40617094)
20. Matza LS, Zyczynski TM, Bavendam T (2004) A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why? Curr Urol Rep 5 (5):336-342
21. Abrams P, Artibani W, Gajewski JB, Hussain I (2006) Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology 68(2 Suppl):17-28 (Pubitemid 44189490)
22. Brubaker L, Chapple C, Coyne KS, Kopp Z (2006) Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 8(2 Suppl):3-8 (Pubitemid 44189491)